Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma

Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy. Since monotherapy in cancer is generally not providing long-lasting clinical responses, we here...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Van Goethem, Alan, Yigit, Nurten, Moreno-Smith, Myrthala, Vasudevan, Sanjeev A., Barbieri, Eveline, Speleman, Frank, Shohet, Jason, Vandesompele, Jo, Van Maerken, Tom
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5593624/
https://ncbi.nlm.nih.gov/pubmed/28915653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18982
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars